Relugolix – The novel oral androgen deprivation therapy for prostate cancer

Relugolix – The novel oral androgen deprivation therapy for prostate cancer

Bibliographic Details
Main Author:	Rahul Jena
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2020;volume=36;issue=4;spage=327;epage=328;aulast=Jena

Similar Items

Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
by: Patrick Campbell, et al.
Published: (2024-11-01)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
by: Kristene Myklak, et al.
Published: (2011-01-01)

Metabolic changes in patients with prostate cancer with androgen deprivation therapy
by: Maxim N. Peshkov, et al.
Published: (2020-06-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
by: Jen‐Tsan Chi, et al.
Published: (2020-06-01)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
by: Safae Terrisse, et al.
Published: (2022-11-01)

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
by: Allison B. Reiss, et al.
Published: (2024-10-01)

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
by: Allison B. Reiss, et al.
Published: (2023-12-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
by: Shangwei Zhong, et al.
Published: (2022-02-01)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
by: Julia Lipianskaya, et al.
Published: (2014-08-01)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
by: Uri Amit, et al.
Published: (2019-06-01)

Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
by: Pietro Enea Lazzerini, et al.
Published: (2020-05-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
by: Tatenuma T, et al.
Published: (2023-08-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
by: Rajan, P, et al.
Published: (2014)

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy
by: Rajan, P, et al.
Published: (2014)

Comparison of the duration of androgen deprivation therapy in prostate cancer-RADICALS-HD trial
by: Prabhu E. Rajendran
Published: (2025-01-01)

Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy
by: S. P. Mironov, et al.
Published: (2021-09-01)

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
by: Lior Z. Braunstein, et al.
Published: (2014-01-01)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
by: Giuseppe Di Lorenzo, et al.
Published: (2022-03-01)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
by: Gabriela Silvia Gheorghe, et al.
Published: (2021-08-01)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
by: Marsha M. van Oostwaard, et al.
Published: (2023-02-01)

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer
by: Chaiyut Kongseang, et al.
Published: (2017-03-01)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
by: Brian De, et al.
Published: (2022-11-01)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
by: Mayhew Richard G, et al.
Published: (2011-09-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Dong‐Yi Chen, et al.
Published: (2023-10-01)

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
by: Jennifer Dunsmore, et al.
Published: (2024-09-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de-implementation strategies
by: Ted A. Skolarus, et al.
Published: (2024-04-01)

Frailty of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review
by: Jeongok Park, et al.
Published: (2024-04-01)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
by: Pawan Vasudeva, et al.
Published: (2008-01-01)

Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
by: Ippei Kojima, et al.
Published: (2019-12-01)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
by: Richard Shore, et al.
Published: (2021-06-01)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
by: Lee C, et al.
Published: (2012-03-01)